{"id":532410,"date":"2021-03-02T19:18:02","date_gmt":"2021-03-02T19:18:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=532410"},"modified":"2021-03-02T19:18:02","modified_gmt":"2021-03-02T19:18:02","slug":"nonsmall-cell-lung-cancer-nsclc-competitive-landscape-2020-emerging-therapies-and-key-pharma-players-involved","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-nsclc-competitive-landscape-2020-emerging-therapies-and-key-pharma-players-involved_532410.html","title":{"rendered":"Non-Small Cell Lung Cancer (NSCLC) Competitive Landscape 2020: Emerging Therapies and Key pharma players involved"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1614596351.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Non-Small Cell Lung Cancer (NSCLC) Competitive Landscape 2020: Emerging Therapies and Key pharma players involved\" src=\"https:\/\/www.abnewswire.com\/uploads\/1614596351.jpeg\" alt=\"Non-Small Cell Lung Cancer (NSCLC) Competitive Landscape 2020: Emerging Therapies and Key pharma players involved\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cNon-Small Cell Lung Cancer (NSCLC) \u2013 Pipeline Insights, 2021,\u201d report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<span data-mce-mark=\"1\">&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Non-Small Cell Lung Cancer (NSCLC) &ndash; Pipeline Insights, 2021<\/strong><\/a>,&rdquo;<\/span>&nbsp;report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Click here to read more.<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>The three main histological subtypes of Non-Small Cell Lung Cancer are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumours start in mucus-producing cells that line the airways.<\/li>\n<li>Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.<\/li>\n<li>Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/cb5a03836ba881111acee238d52a5cab.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Read more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Non-small Cell lung cancer pipeline report<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NSCLC Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Canakinumab: Novartis<\/li>\n<li>Cemiplimab (Libtayo)- Regeneron Pharmaceuticals\/Sanofi<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/non-small-cell-lung-cancer-nsclc-pipeline-insight<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Introduction<\/strong><\/li>\n<li><strong>Executive Summary<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer: Overview<\/strong><\/li>\n<li><strong>Pipeline Therapeutics<\/strong><\/li>\n<li><strong>Therapeutic Assessment<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/strong><\/li>\n<li><strong>In-depth Commercial Assessment<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer Collaboration Deals<\/strong><\/li>\n<li><strong>Late Stage Products (Phase III)<\/strong><\/li>\n<li><strong>Avelumab: Merck<\/strong><\/li>\n<li><strong>Mid Stage Products (Phase II)<\/strong><\/li>\n<li><strong>Eftilagimod: Immutep Limited<\/strong><\/li>\n<li><strong>Poziotinib: Hanmi Pharmaceutical Company Limited<\/strong><\/li>\n<li><strong>Early Stage Products (Phase I)<\/strong><\/li>\n<li><strong>DZD 9008: Dizal Pharmaceutical<\/strong><\/li>\n<li><strong>TY-9591: TYK Medicines, Inc.<\/strong><\/li>\n<li><strong>Pre-clinical and Discovery Stage Products<\/strong><\/li>\n<li><strong>Inactive Products<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer Key Companies<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer Key Products<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer- Unmet Needs<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer- Market Drivers and Barriers<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer- Future Perspectives and Conclusion<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer Analyst Views<\/strong><\/li>\n<li><strong>Non-Small Cell Lung Cancer Key Companies<\/strong><\/li>\n<li><strong>Appendix<\/strong><\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Download report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-pipeline-insight<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/><span>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><span><br \/><\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=nonsmall-cell-lung-cancer-nsclc-competitive-landscape-2020-emerging-therapies-and-key-pharma-players-involved\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=nonsmall-cell-lung-cancer-nsclc-competitive-landscape-2020-emerging-therapies-and-key-pharma-players-involved\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cNon-Small Cell Lung Cancer (NSCLC) \u2013 Pipeline Insights, 2021,\u201d report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/nonsmall-cell-lung-cancer-nsclc-competitive-landscape-2020-emerging-therapies-and-key-pharma-players-involved_532410.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-532410","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=532410"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/532410\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=532410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=532410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=532410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}